UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

November 4 18, 2025 (November 4 18, 2025)

Date of Report (date of earliest event reported)

CUMBERLAND PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)


Tennessee	001-33637	62-1765329
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203

(Address of Principal Executive Offices)

(615) 255-0068

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	CPIX	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 21.~~02 Results~~01 ofEntry ~~Operations~~into ~~and~~a ~~Financial~~Material ~~Condition~~Definitive Agreement.

On November 4 18, 2025, Cumberland Pharmaceuticals Inc. (the "“Company” or “Cumberland”) and Pinnacle Bank ("Pinnacle") ~~issued~~fully aexecuted ~~press~~the ~~release~~First ~~which~~Amendment ~~provided~~to aAmended ~~company~~and ~~update~~Restated Revolving Credit Note and ~~the~~Second ~~financial~~Amendment ~~results~~to ~~for~~Amended and Restated Revolving Credit Loan Agreement (the ~~three~~"Amendment"). The ~~and~~original ~~nine~~Pinnacle ~~months~~agreement ~~ended~~was dated September 305, ~~2025~~2023. AThe ~~copy~~Amendment provides for a principal available for borrowing of up to $15 million. The Company has the ~~press~~right ~~release~~to isrequest ~~attached~~an asincrease ~~Exhibit~~of ~~99.1~~up to ~~this~~an ~~Current~~additional ~~Report~~$10 onmillion. The ~~Form~~aggregate ~~8-K~~principal ~~and~~funding isamount ~~incorporated~~remains byunchanged ~~reference~~of ~~into~~up ~~this~~to ~~Item~~$25 2million.~~02.~~

~~This~~Cumberland ~~information~~ is ~~furnished~~subject ~~pursuant~~ to ~~Item~~a ~~2.02~~financial ~~of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934~~covenant, asmaintenance ~~amended (the "Exchange Act"), or otherwise subject to the liabilities~~ of ~~that~~a ~~section,~~Minimum ~~unless~~Fixed ~~specifically~~Charge ~~incorporated~~Coverage byRatio ~~reference~~determined inon a ~~document~~quarterly ~~filed~~basis, ~~under~~along ~~the~~with ~~Securities~~Borrowing ~~Act~~Base ~~of 1933~~Requirements, as ~~amended, or the Exchange Act~~defined. ByThe ~~filing~~interest ~~this~~rate ~~report~~ on ~~Form~~funds ~~8-K~~borrowed ~~and~~is ~~furnishing~~based ~~this~~on ~~information,~~Benchmark ~~the~~Term ~~Company~~SOFR ~~makes~~plus no2.75%. ~~admission~~Borrowings asunder to the ~~materiality~~line of ~~any~~credit ~~information~~are incollateralized ~~this~~by ~~report~~substantially ~~that~~all isof ~~required~~the toCompany’s ~~be disclosed solely by Item 2~~assets.~~02.~~

The Amendment extends the maturity date to October 1, 2027.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K that relates to the creation of a direct financial obligation of the Company is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.						Description
99.1						Press release dated November 4, 2025
10.1						First Amendment to Amended and Restated Revolving Credit Note and Second Amendment to Amended and Restated Revolving Credit Loan Agreement, dated as of November 12, 2025, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

Dated: November 4, 2025

By:

/s/ John Hamm

Dated: November 21, 2025

By:

/s/ John Hamm

John Hamm

Chief Financial Officer

Filing Compare · CUMBERLAND PHARMACEUTICALS INC